PREMIUM Migraine Trial

NCT ID: NCT00355056

Last Updated: 2020-07-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Purpose of this study is to evaluate the impact of percutaneous closure of a patent foramen ovale (PFO) (a hole in the heart), using the AMPLATZER PFO Occluder, on the incidence of migraine headaches.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to evaluate whether percutaneous PFO closure is effective in reducing the incidence of disabling migraine headaches in patients who are refactory to medical treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Headaches Patent Foramen Ovale

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medical Management

Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).

Group Type SHAM_COMPARATOR

Sham Procedure

Intervention Type OTHER

Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.

PFO Closure

Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.

Group Type EXPERIMENTAL

AMPLATZER PFO Occluder

Intervention Type DEVICE

Patients in this arm will receive the AMPLATZER PFO Occluder device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sham Procedure

Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.

Intervention Type OTHER

AMPLATZER PFO Occluder

Patients in this arm will receive the AMPLATZER PFO Occluder device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects diagnosed as having migraine headaches both with and without aura
* Have a Patent Foramen Ovale (PFO)
* A migraine history and show a refractoriness to medical treatment
* Willing to participate in follow-up visits

Exclusion Criteria

* Subjects whose primary headaches are other than migraine headaches
* Who overuse migraine treatments
* With a clinical history of stroke or Transient Ischemic Attack (TIA)
* With contraindication to aspirin therapy and Clopidogrel
* Pregnant or desire to become pregnant within the next year
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sherman Sorensen, M.D.

Role: PRINCIPAL_INVESTIGATOR

Intermountain Medical Center

Stephen Silberstein, M.D.

Role: PRINCIPAL_INVESTIGATOR

Thomas Jefferson University

Jonathan Tobis, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Andrew Charles, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph's Hospital & Medical Center

Phoenix, Arizona, United States

Site Status

UCLA School of Medicine

Los Angeles, California, United States

Site Status

Memorial Hospital

Colorado Springs, Colorado, United States

Site Status

Swedish Medical Center

Englewood, Colorado, United States

Site Status

Medical Center of the Rockies

Fort Collins, Colorado, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

St. Cloud Hospital

Saint Cloud, Minnesota, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

St. Johns's Mercy Medical Center

St Louis, Missouri, United States

Site Status

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, United States

Site Status

Children's Heart Center Las Vegas

Las Vegas, Nevada, United States

Site Status

Mercy Hospital of Buffalo

Buffalo, New York, United States

Site Status

University of Rochester Medical School

Rochester, New York, United States

Site Status

Pinnacle Health Hospitals

Harrisburg, Pennsylvania, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

The Methodist Hospital

Houston, Texas, United States

Site Status

St. Mark's Hospital

Salt Lake City, Utah, United States

Site Status

Intermountain Medical Center

Salt Lake City, Utah, United States

Site Status

Inova Healthcare Services

Falls Church, Virginia, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

St. Luke's Medical Center

Milwaukee, Wisconsin, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

Reference Type DERIVED
PMID: 29191325 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AGA-010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COMPETE Cohort Study
NCT06033937 RECRUITING